英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
BMS-5
|
1338247-35-0 |
BMS-5
|
LIMKI-3;BMS5;BMS 5;LIMKI3;LIMKI 3;BMS 5;BMS5
|
C17H14Cl2F2N4OS |
431.287066 | |
Lemborexant
|
1369764-02-2 |
莱博雷生
|
CS-2189;莱博雷生;(1R,2S(-2-[(2,4-DIMETHYLPYRIMIDIN-5-YL(OXYMETHYL]-2-(3-FLUOROPHENYL(-N-(5-FLUOROPYRIDIN-2-YL(CYCLOPROPANE-1-CARBOXAMIDE
|
C22H20F2N4O2 |
410.416606 | |
2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine
|
160098-96-4 |
SCH58261
|
CS-2187;7H-吡唑并[4,3-E][1,2,4]三氮唑并[1,5-C]嘧啶-5-胺,2-(2-呋喃基)-7-(2-苯基乙基)-;2-(呋喃-2-基)-7-苯乙基-7H-吡唑并[4,4]三唑并[1,5-C]嘧啶-5-胺;2-(2-呋喃基)-7-(2-苯基乙基)-7H-吡唑并[4,4]噻唑并[1,5-C]嘧啶-5-胺;活性分子 SCH58261;SCH-58261;SCH 58261
|
C18H15N7O |
345.365 | |
Vacquinol-1
|
5428-80-8 |
Vacquinol-1
|
|
C21H21ClN2O |
352.862 | |
LJI308
|
1627709-94-7 |
NULL
|
LJI-308;LJI 308;LJI308;LJI 308;LJI308
|
C21H18F2N2O2 |
368.3766264 | |
EPZ015866
|
1616391-87-7 |
GSK591 (EPZ-15866)
|
CS-2179;EPZ-015866;EPZ 015866;EPZ-015866;EPZ 015866;GSK-591;GSK 591;GSK3203591;GSK-3203591;GSK 3203591
|
C22H28N4O2 |
380.48332 | |
Solcitinib-GSK 2586184 | GLPG 0778
|
1206163-45-2 |
SOLCITINIB
|
CS-2178;索西替尼;GLPG 0778;GLPG-0778;GLPG 0778;GSK 2586184;GLPG-0778;GSK-2586184
|
C22H23N5O2 |
389.45032 | |
ML281
|
1404437-62-2 |
ML281
|
CS-2166;ML 281;ML-281;N-[2-(3,4-二氢-3-氧代-2-喹喔啉基)-4-(1-甲基乙基)苯基]-2-噻吩甲酰胺
|
C22H19N3O2S |
389.47016 | |
A-1210477
|
1668553-26-1 |
A-121477
|
7-[5-[[4-[4-[(二甲基氨基)磺酰基]-1-哌嗪基]苯氧基]甲基]-1,3-二甲基-1H-吡唑-4-基]-1-[2-(4-吗啉基)乙基]-3-[3-(1-萘基氧基)丙基]-1H-吲哚-2-羧酸
|
C46H55N7O7S |
850.0366 | |
PIBOSEROD,2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE, N-((1-BUTYL-4-PIPERIDINYL)METHYL)-3,4-DIHYDRO-
|
152811-62-6 |
PIBOSEROD
|
N-[(1-丁基哌啶-4-基)甲基]-3,4-二氢-2H-[1,3]恶嗪并[3,2-A]吲哚-10-甲酰胺;哌波色罗
|
C22H31N3O2 |
369.506 | |
RBC 8
|
361185-42-4 |
RBC8
|
CS-2174;RBC8>98%;RBC-8;RBC 8;CS-2130
|
C25H20N4O3 |
424.4513 | |
(2Z,5Z)-5-(3-Chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one
|
854107-55-4 |
PONESIMOD
|
CS-2110;PONESIMOD,ACT-128800;CS-2358;ACT128800;ACT 128800;ACT-128800
|
C23H25ClN2O4S |
460.9736 | |
BPR1J-097
|
1327167-19-0 |
BPR1J-97
|
CS-2096;BPR1J-097;BPR1J 097;BPR1J097;CS-2356
|
C27H28N6O3S |
516.61462 | |
A-366
|
1527503-11-2 |
A-366
|
CS-2077;A-366;A366;A 366
|
C19H27N3O2 |
329.43658 | 808-907-0 |
STK321130
|
923562-23-6 |
STK32113
|
CS-2070;5-[(5-氯-1H-吡咯并[2,3-B]吡啶-3-基)甲基]-N-[[4-(三氟甲基)苯基]甲基]-2-吡啶胺
|
C21H16ClF3N4 |
416.82675 | |
QNZ46
|
1237744-13-6 |
QNZ46
|
CS-2059;QNZ-46;QNZ 46;QNZ46;CS-2438;QNZ 46;QNZ-46;4-[6-甲氧基-2-[(1E)-2-(3-硝基苯基)乙烯基]-4-氧代-3(4H)-喹唑啉基]苯甲酸
|
C24H17N3O6 |
443.40828 | |
CC-223
|
1228013-30-6 |
CC-223
|
CS-2039;7-[6-(2-羟基丙-2-基)吡啶-3-基]-1-(反式-4-甲氧基环己基)-3,4-二氢吡嗪并[2,3-B]吡嗪-2(1H)-酮;CS-2163;CC223;CC 223;ONATASERTIB(CC 223,ATG-008)
|
C21H27N5O3 |
397.47078 | |
PFI-4
|
900305-37-5 |
PFI-4
|
PFI4;PFI 4;N-[2,3-二氢-1,3-二甲基-2-氧代-6-(1-吡咯烷基)-1H-苯并咪唑-5-基]-2-甲氧基苯甲酰胺
|
C21H24N4O3 |
380.448 | |
BI605906
|
960293-88-3 |
/
|
CS-2032
|
C17H22F2N4O3S2 |
||
PQR309
|
1225037-39-7 |
PQR39
|
PQR-309, >98%;5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine;PI3K-IN-2;PQR309;Bimiralisib;PQR309 Bimiralisib;2-Pyridinamine,5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-;Bimiralisib (PQR309)(free base)
|